Vididencel in CML-CP Patients With MRD

The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with tyrosine kinase inhibitor (TKI). Patients may not receive any direct medical benefit from participating. Participants in the study should have been treated with TKI for at least 24 months prior to enrolment. This TKI must be of the same type throughout the 24 months. Participation in the active period of the study will take about 5 months after which patients will be foll

Trial Details

NCT ID
NCT07651878
Phase
PHASE1
Sponsor
Mendus
Status
RECRUITING
Cancer Type
Chronic Myeloid (CML) Leukemia
Interventions
  • vididencel
Locations (sample)
  • Bergen, Norway|60.39299,5.32415

Key Eligibility Criteria

  • Male or female aged ≥ 18 years at the time of informed consent.
  • Signed and dated informed consent document indicating that the participant has been informed of all the pertinent aspects of the trial prior to any…
  • Willing to comply with clinical trial instructions and requirements.
  • Confirmed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) (according to ELN 2025) treated with the same T…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Myeloid (CML) Leukemia Trials on Trialify →